Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BeiGene (BGNE)
NASDAQ:BGNE
BeiGene (BGNE) Stock Price & Analysis
659 Followers
BGNE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$126.97 - $245.74
Previous Close$162.17
Volume108.51K
Average Volume (3M)213.33K
Market Cap
$17.53B
Enterprise Value$20.69B
Total Cash (Recent Filing)$3.17B
Total Debt (Recent Filing)$6.33B
Price to Earnings (P/E)-21.4
Beta1.19
Next Earnings
Aug 23, 2024EPS Estimate
-$2.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.57
Shares Outstanding104,578,798
10 Day Avg. Volume189,952
30 Day Avg. Volume213,326
Standard Deviation0.14
R-Squared0.05
Alpha0.00674
Financial Highlights & Ratios
Price to Book (P/B)4.84
Price to Sales (P/S)6.90
Price to Cash Flow (P/CF)-19.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.56
Enterprise Value/Gross Profit9.95
Enterprise Value/Ebitda-24.16
Forecast
1Y Price Target
$250.38Price Target Upside54.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
BeiGene News
Bulls Say, Bears Say
Bulls Say
Financial HealthThe company's net loss narrowed significantly, showing improved financial health.
Intellectual PropertyUS patent office granted BGNE's petition for a post-grant review which could invalidate a competitor's patent, potentially avoiding a trial.
Product PerformanceProduct sales continued beating expectation with strong performance driven by market share gain and expansion of reimbursement coverage.
Bears Say
Financial PerformanceMonthly sales of Beigene's self-developed drugs pamiparib and zanubrutinib have seen a significant decline, indicating potential revenue challenges.
Market CompetitionIntense competition and price-cut pressure in the China market pose challenges to the company's business development.
Stock ValuationThe analyst has lowered the price objective to US$163 from US$200 and reiterated a Neutral rating, reflecting a cautious outlook on the stock.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BGNE FAQ
What was BeiGene’s price range in the past 12 months?
BeiGene lowest stock price was $126.97 and its highest was $245.74 in the past 12 months.
What is BeiGene’s market cap?
Currently, no data Available
When is BeiGene’s upcoming earnings report date?
BeiGene’s upcoming earnings report date is Aug 23, 2024 which is in 101 days.
How were BeiGene’s earnings last quarter?
BeiGene released its earnings results on May 08, 2024. The company reported -$2.41 earnings per share for the quarter, beating the consensus estimate of -$3.094 by $0.684.
Is BeiGene overvalued?
According to Wall Street analysts BeiGene’s price is currently Undervalued.
Does BeiGene pay dividends?
BeiGene does not currently pay dividends.
What is BeiGene’s EPS estimate?
BeiGene’s EPS estimate is -$2.05.
How many shares outstanding does BeiGene have?
BeiGene has 95,667,570 shares outstanding.
What happened to BeiGene’s price movement after its last earnings report?
BeiGene reported an EPS of -$2.41 in its last earnings report, beating expectations of -$3.094. Following the earnings report the stock price went up 2.417%.
Which hedge fund is a major shareholder of BeiGene?
Among the largest hedge funds holding BeiGene’s share is Baker Bros Advisors LP. It holds BeiGene’s shares valued at 2B.
---
BeiGene Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$250.38 (54.39% Upside)
$250.38 (54.39% Upside)
Blogger Sentiment
Bullish
BGNE Sentiment 83%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $66.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.96%
12-Months-Change
Fundamentals
Return on Equity
-20.87%
Trailing 12-Months
Asset Growth
-4.85%
Trailing 12-Months
Company Description
BeiGene
BeiGene, Ltd.is a biopharmaceutical company. The company primarily focuses on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer.
---
BGNE Stock 12 Month Forecast
Average Price Target
$250.38
▲(54.39% Upside)
Technical Analysis
Best Analysts Covering BGNE
1 Year
1 Year Success Rate
15/23 ratings generated profit
1 Year Average Return
+29.45%
reiterated a buy rating 6 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 65.22% of your transactions generating a profit, with an average return of +29.45% per trade.
---